Rocket PharmaceuticalsRCKT
RCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
172% more call options, than puts
Call options by funds: $3.92M | Put options by funds: $1.44M
168% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 41
37% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 35
4% more funds holding
Funds holding: 224 [Q4 2024] → 234 (+10) [Q1 2025]
2.06% less ownership
Funds ownership: 103.1% [Q4 2024] → 101.03% (-2.06%) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
48% less capital invested
Capital invested by funds: $1.38B [Q4 2024] → $722M (-$655M) [Q1 2025]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.50
16%
downside
Avg. target
$19.46
558%
upside
High target
$44
1,386%
upside
14 analyst ratings
10 positive
71%
4 neutral
29%
0 negative
0%
UBS Colin Bristow | 69%upside $5 | Buy Maintained | 17 Jun 2025 |
Canaccord Genuity Whitney Ijem | 272%upside $11 | Buy Maintained | 3 Jun 2025 |
B of A Securities Jason Zemansky | 204%upside $9 | Buy Maintained | 28 May 2025 |
BMO Capital Kostas Biliouris | 170%upside $8 | Outperform Maintained | 28 May 2025 |
Scotiabank Greg Harrison | 542%upside $19 | Sector Outperform Maintained | 28 May 2025 |
Financial journalist opinion
Based on 159 articles about RCKT published over the past 30 days
Neutral
GlobeNewsWire
11 hours ago
August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Neutral
GlobeNewsWire
14 hours ago
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, July 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”).
Neutral
GlobeNewsWire
17 hours ago
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
17 hours ago
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman
SAN FRANCISCO, July 11, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
Neutral
PRNewsWire
18 hours ago
Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) should contact Levi & Korsinsky about pending Class Action - RCKT
NEW YORK , July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025.
Neutral
GlobeNewsWire
1 day ago
The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).
Neutral
GlobeNewsWire
1 day ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), of the important August 11, 2025 lead plaintiff deadline.
Neutral
GlobeNewsWire
1 day ago
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers.
Neutral
PRNewsWire
1 day ago
Contact The Gross Law Firm by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc.(RCKT)
NEW YORK , July 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
2 days ago
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop
PHILADELPHIA , July 9, 2025 /PRNewswire/ -- Berger Montague PC , a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company"). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program.
Charts implemented using Lightweight Charts™